DK3254110T3 - Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1) - Google Patents
Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1) Download PDFInfo
- Publication number
- DK3254110T3 DK3254110T3 DK16702150.0T DK16702150T DK3254110T3 DK 3254110 T3 DK3254110 T3 DK 3254110T3 DK 16702150 T DK16702150 T DK 16702150T DK 3254110 T3 DK3254110 T3 DK 3254110T3
- Authority
- DK
- Denmark
- Prior art keywords
- assess
- expression
- programmed death
- death ligand
- histochemical test
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562111352P | 2015-02-03 | 2015-02-03 | |
| PCT/EP2016/052107 WO2016124558A1 (en) | 2015-02-03 | 2016-02-02 | Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3254110T3 true DK3254110T3 (da) | 2020-05-18 |
Family
ID=55272501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16702150.0T DK3254110T3 (da) | 2015-02-03 | 2016-02-02 | Histokemisk test til vurdering af ekspression af programmeret død-ligand 1 (pd-l1) |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10620211B2 (da) |
| EP (1) | EP3254110B1 (da) |
| DK (1) | DK3254110T3 (da) |
| ES (1) | ES2791950T3 (da) |
| WO (1) | WO2016124558A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108112254B (zh) | 2015-03-13 | 2022-01-28 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| IL255312B (en) * | 2015-05-12 | 2022-08-01 | Genentech Inc | Therapeutic and diagnostic methods for cancer containing a pd–l1 binding antagonist |
| TWI786044B (zh) | 2016-05-13 | 2022-12-11 | 美商再生元醫藥公司 | 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法 |
| JP7525261B2 (ja) * | 2016-09-20 | 2024-07-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 診断用抗ｐｄ－ｌ１抗体およびその使用 |
| KR20240011262A (ko) | 2017-02-21 | 2024-01-25 | 리제너론 파아마슈티컬스, 인크. | 폐암의 치료를 위한 항-pd-1 항체 |
| BR112019025188A2 (pt) | 2017-06-01 | 2020-06-23 | Cytomx Therapeutics, Inc. | Anticorpos anti-pdl1 ativáveis e métodos de uso dos mesmos |
| CN107266572A (zh) * | 2017-07-13 | 2017-10-20 | 无锡傲锐东源生物科技有限公司 | 抗pd‑l1蛋白单克隆抗体及其用途 |
| CN108864284A (zh) * | 2018-04-02 | 2018-11-23 | 南京基诺米医疗科技有限公司 | 兔抗人pd-l1蛋白单克隆抗体制备及其免疫组化用途 |
| KR102567972B1 (ko) | 2018-06-04 | 2023-08-17 | 삼성전자주식회사 | 유기 이미지 센서 |
| AU2020276242B2 (en) | 2019-05-13 | 2025-01-30 | Regeneron Pharmaceuticals, Inc. | Combination of PD-1 inhibitors and LAG-3 inhibitors for enhanced efficacy in treating cancer |
| MX2022014734A (es) | 2020-05-26 | 2023-03-15 | Regeneron Pharma | Metodos de tratamiento del cancer de cuello uterino mediante la administracion del anticuerpo inhibidor de pd-1 cemiplimab. |
| US20230323470A1 (en) | 2020-08-26 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Methods of treating cancer by administering a pd-1 inhibitor |
| IL319877A (en) | 2022-10-03 | 2025-05-01 | Regeneron Pharma | Methods for treating cancer with bispecific EGFR X CD28 antibodies alone or in combination with anti-PD-1 antibodies |
| EP4680342A1 (en) | 2023-03-13 | 2026-01-21 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating melanoma |
| WO2025106736A2 (en) | 2023-11-15 | 2025-05-22 | Regeneron Pharmaceuticals, Inc. | Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating lung cancer |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1564604A (en) | 1925-06-12 | 1925-12-08 | Chas S Hodges | Water wheel |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| JPS61134325A (ja) | 1984-12-04 | 1986-06-21 | Teijin Ltd | ハイブリツド抗体遺伝子の発現方法 |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6005079A (en) | 1992-08-21 | 1999-12-21 | Vrije Universiteit Brussels | Immunoglobulins devoid of light chains |
| PT1621554E (pt) | 1992-08-21 | 2009-07-13 | Univ Bruxelles | Imunoglobtainas desprovidas de cadeias leves |
| US5922855A (en) | 1993-12-17 | 1999-07-13 | Oregon Health Sciences University | Mammalian DNA mismatch repair genes MLH1 and PMS1 |
| AU9550198A (en) | 1997-10-21 | 1999-05-10 | University Court Of The University Of Glasgow, The | Jmy, a co-activator for p300/cbp, nucleic acid encoding jmy and uses thereof |
| MXPA02001878A (es) | 1999-08-23 | 2003-08-20 | Dana Farber Cancer Inst Inc | Moleculas b7-4 novedosas y usos de las mismas. |
| EP1234031B2 (en) | 1999-11-30 | 2021-11-24 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| US6803192B1 (en) | 1999-11-30 | 2004-10-12 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| US6649138B2 (en) | 2000-10-13 | 2003-11-18 | Quantum Dot Corporation | Surface-modified semiconductive and metallic nanoparticles having enhanced dispersibility in aqueous media |
| US20020083888A1 (en) | 2000-12-28 | 2002-07-04 | Zehnder Donald A. | Flow synthesis of quantum dot nanocrystals |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US6670113B2 (en) | 2001-03-30 | 2003-12-30 | Nanoprobes | Enzymatic deposition and alteration of metals |
| WO2003092043A2 (en) | 2001-07-20 | 2003-11-06 | Quantum Dot Corporation | Luminescent nanoparticles and methods for their preparation |
| CA2773566C (en) | 2003-06-24 | 2015-09-15 | Ventana Medical Systems, Inc. | Enzyme-catalyzed metal deposition for the enhanced in situ detection of immunohistochemical epitopes and nucleic acid sequences |
| AU2012211347B9 (en) | 2004-07-20 | 2015-06-18 | Alexion Pharmaceuticals, Inc. | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| DK3428191T3 (da) | 2004-10-06 | 2025-01-02 | Mayo Found Medical Education & Res | B7-h1 og pd-1 til behandling af renalcellekarcinom |
| US7895540B2 (en) | 2006-08-02 | 2011-02-22 | Georgia Tech Research Corporation | Multilayer finite difference methods for electrical modeling of packages and printed circuit boards |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| EP3192811A1 (en) | 2009-02-09 | 2017-07-19 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| IT1395574B1 (it) | 2009-09-14 | 2012-10-16 | Guala Dispensing Spa | Dispositivo di erogazione |
| CN104826106B (zh) | 2009-09-30 | 2019-01-11 | 斯隆凯特林防癌纪念中心 | 用于治疗癌症的组合免疫疗法 |
| NO2504364T3 (da) | 2009-11-24 | 2018-01-06 | ||
| JP2013531801A (ja) | 2010-07-02 | 2013-08-08 | ヴェンタナ メディカル システムズ， インク． | 標的検出のためのハプテンコンジュゲート |
| CN102250911A (zh) | 2011-05-31 | 2011-11-23 | 苏州大学 | 一种可溶性b7-h1定量检测试剂盒 |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| WO2013172926A1 (en) | 2012-05-14 | 2013-11-21 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
| AU2013263076B2 (en) * | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| WO2014022758A1 (en) | 2012-08-03 | 2014-02-06 | Dana-Farber Cancer Institute, Inc. | Single agent anti-pd-l1 and pd-l2 dual binding antibodies and methods of use |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| WO2014165082A2 (en) * | 2013-03-13 | 2014-10-09 | Medimmune, Llc | Antibodies and methods of detection |
| AR095363A1 (es) * | 2013-03-15 | 2015-10-14 | Genentech Inc | Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1 |
| US20160084839A1 (en) * | 2013-04-02 | 2016-03-24 | Marisa Dolled-Filhart | Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue |
| WO2014194293A1 (en) | 2013-05-30 | 2014-12-04 | Amplimmune, Inc. | Improved methods for the selection of patients for pd-1 or b7-h4 targeted therapies, and combination therapies thereof |
| AU2014293154A1 (en) | 2013-07-24 | 2016-02-18 | Dana-Farber Cancer Institute, Inc. | Anti-galectin-1 monoclonal antibodies and fragments thereof |
| GB201316027D0 (en) | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for oesophageal cancer |
| GB201316024D0 (en) | 2013-09-09 | 2013-10-23 | Almac Diagnostics Ltd | Molecular diagnostic test for lung cancer |
| WO2015038538A1 (en) | 2013-09-10 | 2015-03-19 | Medimmune, Llc | Compositions and methods for treating sepsis |
| CN105873606B (zh) | 2013-09-11 | 2020-12-29 | 米迪缪尼有限公司 | 用于治疗肿瘤的抗b7-h1抗体 |
| AU2014339900B2 (en) | 2013-10-25 | 2019-10-24 | Dana-Farber Cancer Institute, Inc. | Anti-PD-L1 monoclonal antibodies and fragments thereof |
| US10241115B2 (en) | 2013-12-10 | 2019-03-26 | Merck Sharp & Dohme Corp. | Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue |
| WO2015124703A1 (en) | 2014-02-24 | 2015-08-27 | Ventana Medical Systems, Inc. | Quinone methide analog signal amplification |
| DK3149042T3 (da) * | 2014-05-29 | 2019-11-04 | Spring Bioscience Corp | PD-L1-antistoffer og anvendelser deraf |
| CA2947687C (en) * | 2014-05-30 | 2021-07-06 | Ventana Medical Systems, Inc. | Multiplex assay for improved scoring of tumor tissues stained for pd-l1 |
| WO2016075095A2 (en) * | 2014-11-10 | 2016-05-19 | Ventana Medical Systems, Inc. | Using contextual information to classify nuclei in histology images |
-
2016
- 2016-02-02 WO PCT/EP2016/052107 patent/WO2016124558A1/en not_active Ceased
- 2016-02-02 DK DK16702150.0T patent/DK3254110T3/da active
- 2016-02-02 EP EP16702150.0A patent/EP3254110B1/en active Active
- 2016-02-02 ES ES16702150T patent/ES2791950T3/es active Active
-
2017
- 2017-07-28 US US15/663,640 patent/US10620211B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170343556A1 (en) | 2017-11-30 |
| WO2016124558A1 (en) | 2016-08-11 |
| US10620211B2 (en) | 2020-04-14 |
| EP3254110A1 (en) | 2017-12-13 |
| EP3254110B1 (en) | 2020-03-18 |
| ES2791950T3 (es) | 2020-11-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL254608A0 (en) | Techniques for automated determination of form responses | |
| DK3538864T3 (da) | Mikrotom | |
| IL254330A0 (en) | Model-based single parameter measurement | |
| SG10202007937SA (en) | PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
| IL252881A0 (en) | Microencapsulated cannabinoid compositions | |
| DK3140653T3 (da) | Direkte immunhistokemianalyse | |
| PT3311169T (pt) | Ensaio modelador | |
| HUE049233T2 (hu) | C9ORF72-expresszió módosítására szolgáló készítmények | |
| DK3384274T3 (da) | Fremgangsmåder til prøvekarakterisering | |
| DK3757214T3 (da) | Sammensætninger til modulering af sod-1-ekspression | |
| DK3119888T3 (da) | Sammensætninger til at modulere ataxin-2-ekspression | |
| EP3349013A4 (en) | AUTOMATED ANALYZER | |
| DK3386548T3 (da) | Inositol-derivater til anvendelse i patologisk krystallisering | |
| EP3343231A4 (en) | AUTOMATED ANALYZER | |
| ME03414B (me) | Imidazopirazinoni kао pde1 inhibitori | |
| EP3538141A4 (en) | LIGAND ILT3 | |
| EP3594691A4 (en) | AUTOMATIC ANALYZER | |
| EP3415921A4 (en) | AUTOMATED ANALYZER | |
| HUE049548T2 (hu) | Berendezés csalétkek tartására | |
| EP3557264A4 (en) | AUTOMATIC ANALYZER | |
| EP3588093A4 (en) | AUTOMATED ANALYZER | |
| EP3438670A4 (en) | AUTOMATED ANALYZER | |
| DK3364189T3 (da) | Immunkromatografisk teststykke | |
| EP3709027A4 (en) | AUTOMATED ANALYZER | |
| EP3588100A4 (en) | AUTOMATIC ANALYZER |